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Abstract
Background: To date, diagnosis of Primary Ciliary Dyskinesia (PCD) remains difficult and challenging. We systematically
evaluated the diagnostic performance of nasal Nitric Oxide (nNO) measurement for the detection of PCD, using either
velum-closure (VC) or non-velum-closure (non-VC) techniques.
Methods: All major electronic databases were searched from inception until March 2015 using appropriate terms.
The sensitivity and specificity of nNO measurement was calculated in PCD patients diagnosed by transmission
electron microscopy, high speed video-microscopy or genetic testing. Summary receiver operating characteristic
(HSROC) curves were drawn using the parameters of the fitted models.
Results: Twelve studies provided data for 13 different populations, including nine case–control (n = 793) and four
prospective cohorts (n = 392). The overall sensitivity of nNO measured by VC techniques was 0.95 (95 % CI 0.91–0.97),
while specificity was 0.94 (95 % CI 0.88–0.97). The positive likelihood ratio (LR+) of the test was 15.8 (95 % CI 8.1–30.6),
whereas the negative likelihood ratio (LR-) was 0.06 (95 % CI 0.04–0.09). For non-VC techniques, the overall sensitivity of
nNO measurement was 0.93 (95 % CI 0.89–0.96) whereas specificity was 0.95 (95 % CI 0.82–0.99). The LR+ of the test
was 18.5 (95 % CI 4.6–73.8) whereas the LR- was 0.07 (95 % CI 0.04–0.12).
Conclusions: Diagnostic accuracy of nNO measurement both with VC and non-VC maneuvers is high and can be
effectively employed in the clinical setting to detect PCD even in young children, thus potentiating early diagnosis.
Measurement of nNO merits to be part of a revised diagnostic algorithm with the most efficacious combination of
tests to achieve PCD diagnosis.
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Background
Primary ciliary dyskinesia (PCD) is a rare, hereditary dis-
order characterized by impaired mucociliary clearance [1].
Apart from situs inversus in ~50 % of the cases, the main
manifestations of the disease are not specific. Neverthe-
less, the associated recurrent sinopulmonary infections
eventually lead to severe chronic lung disease and devel-
opment of bronchiectasis [2, 3].
While some centers began using targeted genetic test-
ing [4], the diagnosis of PCD in the majority of centers
currently relies on an array of different sophisticated
tests namely the High Speed Video Microscopy (HSVM)
for ciliary motility assessment [5], Transmission Electron
Microscopy (TEM) for the examination of cilia ultrastruc-
ture [6] and nasal nitric oxide (nNO) measurement [7].
The diversity of the employed diagnostic tests reflects the
lack of a golden diagnostic standard and the weaknesses
and inaccuracies that characterize each of these tests. In
particular, TEM examination of ciliary axonemes exhibits
normal ultrastructure in confirmed patients with biallelic
mutations in certain disease-causing genes such as
DNAH11 [8], while the motility patterns observed by
HSVM vary widely depending on the implicated genetic
variant [9, 10].
Nasal nitric oxide (nNO) is abnormally low in PCD pa-
tients [11] and it has been part of the diagnostic work-up
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in many PCD centers [12]. Current American Thoracic
Society/European Respiratory Society (ATS/ERS) guide-
lines for nNO measurements recommend air aspiration
via a nasal probe while the subject exhales through the
mouth against resistance in order to maintain velum clos-
ure. Alternative techniques to maintain velum closure
such as breath hold or pursed- lip breathing via the mouth
are also acceptable [13]. However, velum closure requires
cooperation and this precludes the performance of these
techniques in young children. Few reports have investi-
gated the discriminative ability of nNO measurements
with the velum open as in the case of tidal breathing [3, 14]
with encouraging findings for the usefulness of this tech-
nique in screening for PCD in younger children and adults
unable to perform velum closure.
In view of the above specific restrictions and weak-
nesses, for the clinicians and the patients it remains of
key importance to appraise the potential diagnostic value
of each of the available diagnostic tests for PCD, in order
to find its place in the armamentarium for elicitation of
the diagnosis of the disease. A recent systematic review
and meta-analysis summarized the published evidence
on the measurement of nNO in PCD and reported on
the mean difference of nNO production values obtained
during velum closure techniques in PCD patients versus
healthy controls (231 nL/min, 95 % CI: 193.3–268.9) and
cystic fibrosis patients (114.1 nL/min, 95 % CI: 101.5–
126.8) [15]. However, that report did not perform a meta-
analysis on the diagnostic accuracy of nNO measurements
in order to provide synthesized data on the potential diag-
nostic value this test may have in future algorithms for
PCD diagnosis, which would be particularly informative in
clinical decision making. The aim of this study was to sys-
tematically evaluate the diagnostic performance of nNO
measurement as obtained either with a velum-closure or a
non-velum-closure technique in screening for PCD so as
to provide appropriate summary estimates of diagnostic
accuracy with each breathing technique and demonstrate
the summary trade-off between sensitivity and specificity
across the included studies.
Methods
Search strategy and selection criteria
The electronic databases PubMed, SCOPUS, Cochrane
Database of Systematic Reviews and Google Scholar
were searched from inception until March 2015 using
the keywords: ‘nasal nitric oxide’, “nNO”, “nasal NO”,
“Primary Ciliary Dyskinesia”, “PCD”, “lung”, “pulmon-
ary”, “pulm*”, “cilia” either in the title or the abstract or
using MeSH terms. The references of eligible studies
were further examined for possible missing articles. We
included studies which were identified after two re-
viewers (PK, SIP) independently screened the title and
abstract of the obtained search results. Final selection
was based on full text evaluation. Any disagreements were
resolved by discussion and in case of discrepancy, by a third
researcher (PKY). As this study is based on a systematic re-
view of the previously published literature, an ethical ap-
proval was not obtained, since there is no potential of
participant identification and ethical approval and consent
was already obtained at the individual study level. The
guidelines of the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) were followed.
The validity of each primary study was assessed using the
Quality Assessment of Diagnostic Accuracy Studies −2
(QUADAS-2) tool [16], that evaluates the risk of bias and
applicability of diagnostic accuracy studies. It consists of
four key domains: patient selection, index test, reference
standard, flow and timing. Each is assessed in terms of risk
of bias and the first three in terms of issues regarding
applicability.
Studies were considered eligible if they provided data on
the sensitivity and specificity of nNO for the diagnosis of
PCD in order to construct a 2 × 2 table for each study cal-
culating true positives (TP), false negatives (FN), false pos-
itives (FP) and true negatives (FN) for the presence or not
of PCD according to nNO values set as a cut-off in each
study. In some studies, the numbers were not provided
per se but it was possible to extract them from other
manuscript data sources. In case of incomplete informa-
tion, we contacted the authors of the primary studies.
Studies that reported only mean values of nNO were not
included in our analyses as they did not provide data for
computing summary diagnostic accuracy estimates (sensi-
tivity, specificity, positive and negative likelihood ratio).
Disease status in each selected study was required to have
been confirmed by TEM and/or HSVM or genetic testing.
Additional information on NO analyzer type, flow rate
and breathing maneuver was also collected and used in
data synthesis. Studies that did not report the equipment
and flow rate used were not considered eligible as well as
studies that may have used flow rate outside of the ATS/
ERS recommended range (0.25–3 L/min) [13]. Cut-off
values for the nNO test, were usually reported in parts per
billion (ppb) and were transformed to NO production rate
units (nl/min), using the conversion formula concentra-
tion (ppb) × sampling rate (L/min) as used previously [7],
in order to account for the used different flow rates.
Breathing maneuvers such as breath hold (BH) and exhal-
ation against resistance (ER) were categorized as velum
closure (VC) techniques and in case of both maneuvers
performed by the study subjects; only results for the ER
maneuver were included as the most validated tech-
nique according to ATS/ERS guidelines [13]. For studies
employing the non-velum closure (non-VC) technique,
only results of nNO measurements that were performed
during tidal breathing (TB) with mouth open were in-
cluded in the meta-analysis.
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Data extraction
The name of author, study design, publication year,
country of origin, study population sample size, age dis-
tribution of study population subgroups, nNO cut-off
levels, information on the measurement method and the
test(s) used for the diagnosis of PCD were recorded for
each study. Data on the values of TP, TN, FP, FN were
extracted independently by two reviewers (PK, SIP). A
third investigator (PKY) settled any discrepancies and
consensus was reached for all data.
Analysis
A bivariate model was used to calculate estimates of over-
all sensitivity and overall specificity. We fitted a two-level
mixed logistic regression model conditional on the sensi-
tivity and the specificity of each study and a bivariate nor-
mal model for the sensitivity and specificity between
studies [17]. This method combines information from
multiple thresholds and the output is expressed as a hier-
archical summary receiver operator curve (HSROC). The
HSROC describes the relationship between sensitivity and
specificity derived from the individual receiver operator
curves (ROC) of each study. Following this method, it de-
scribes the ‘average’ relationship between a continuous
cut-off value and discriminatory ability in the ‘average’
population. This maximizes the amount of information
used in the evidence synthesis and better represents the
available data. The advantage of this method is that it al-
lows clinicians to estimate how changing thresholds will
alter the diagnostic utility of the test under study. All
calculations are performed using STATA (Version 12, Sta-
taCorp, College Station, Texas) with the commands
metandi and metandi plots for analyses of four studies
and above [18].
We also reported the summary likelihood ratios across
all studies. These measures also combine in their calcu-
lation both sensitivity and specificity. Positive likelihood
ratio (LR+) is the ratio of sensitivity/(1-specificity),
whereas negative likelihood ratio (LR-) is defined as the
ratio of (1-sensitivity)/specificity. When there is absolutely
no discriminating ability for a diagnostic test, both ratios
are equal to 1. The discriminating ability is better with
higher LR+ and lower LR-. A good diagnostic test has typ-
ically LR+ greater than 5.0 and LR- less than 0.2 [19].
VC and non-VC measurements were analyzed separ-
ately and this allowed us to arrive at estimates on overall
sensitivity, specificity and likelihood ratios for nNO de-
pending on VC status. We also performed a sensitivity
analysis including only studies in which PCD status was
defined by TEM and at least one more diagnostic test,
with the rationale to examine whether the diagnostic ac-
curacy of nNO measurement differs with the inclusion of
a more representative spectrum of PCD population. Mea-
surements of nNO were compared to PCD diagnosis
obtained through a combination of tests which included
TEM and HSVM or DNA testing.
Results
Eligible studies
Of the 1940 items retrieved through online search, 1866
were excluded based on the title and abstract and the
remaining 74 were downloaded for detailed, full text as-
sessment. Two additional studies were identified through
references screening and were also evaluated. Studies with
overlapping populations were cross-checked and final se-
lection was based on the largest number of participating
PCD patients. In summary, 26 studies did not provide data
on sensitivity and specificity, 13 items involved overlap-
ping populations, 15 items were review papers while the
remaining items that were excluded were case reports (2),
editorials (3) and guidelines papers (2) (Fig. 1). Of the total
76 studies assessed in detail, 15 provided enough data for
the construction of a 2×2 table. Among these, two studies
did not report type of NO analyzer and flow rate and des-
pite our effort to obtain this information after contacting
the authors, this was not feasible and they were excluded
from the analysis [20, 21]. Finally, quantitative synthesis
included data on 13 different populations from 12 studies
(Marthin et al. included data on more than one popula-
tion) and two separate analyses were carried out, based on
the employed breathing maneuver.
Study characteristics
Descriptive characteristics of the included studies are pre-
sented in Table 1. From 12 studies, 325 PCD patients and
711 non-PCD subjects were included in the meta-analysis
for the diagnostic performance of VC nNO testing. In the
case of non-VC nNO testing, 210 PCD patients and 471
non-PCD subjects from seven studies were included. The
majority of the studies were performed in Western Europe
and only two in North America. Four studies evaluated the
diagnostic efficacy of nNO in cohorts of referred suspect
patients for PCD testing [7, 22–24] whereas the rest of the
studies had a case–control design. Controls were non-
PCD subjects, either healthy subjects only [22, 25–28] or
healthy subjects and patients with other respiratory dis-
eases [14, 29–31].
The number of PCD patients (range: 9–59) and controls
(range: 14–188) per case–control study varied widely. All
case–control studies confirmed PCD status by TEM find-
ings while in 55 % of them HSVM was also performed. Of
the four prospective studies, Beydon et al. used a combin-
ation of TEM, HSVM and genetic testing to confirm PCD
diagnosis [24] while Marthin et al. used TEM and HSVM
in their cohort of consecutive referrals [22]. Leigh et al.
confirmed PCD via a combination of ultrastructure as-
sessment and genetic testing [7] while the smallest cohort
study confirmed PCD only via ultrastructural assessment
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[23]. The sensitivity and specificity of each included study
with VC and non-VC technique are shown in Fig. 2.
Quality assessment
Reporting of the meta-analysis is based on PRISMA
guidelines [32]. Based on the QUADAS-2 tool, the quality
assessment of the primary studies is shown in Table 2. In
general, the analyzed studies had overall reasonably good
methodology and this offers relative reassurance that re-
sults have not been substantially influenced from bias.
Data synthesis
The overall sensitivity of abnormal (low) nNO measured
by VC techniques for all the included studies was 0.95
(95 % CI 0.91–0.97), while the specificity was 0.94 (95 %
CI 0.88–0.97). The LR+ of the test was 15.8 (95 % CI
8.1–30.6), whereas the LR- was 0.06 (95 % CI 0.04–0.09).
The HSROC curve is shown in Fig. 3.
For the non-VC techniques the overall sensitivity of
nNO to detect PCD was 0.93 (95 % CI 0.89–0.96)
whereas the specificity was 0.95 (95 % CI 0.82–0.99).
The LR+ of the test was 18.5 (95 % CI 4.6–73.8) whereas
the LR- was 0.07 (95 % CI 0.04–0.12). The HSROC
curve is shown in Fig. 3.
When we performed a sensitivity analysis, to calculate
the nNO diagnostic accuracy in studies that only in-
cluded PCD populations diagnosed by more than one
test (combination of TEM and HSVM or genetic testing)
[7, 14, 22, 24, 26, 27, 30], the results did not change
significantly. Similarly, after performing a post hoc
Fig. 1 PRISMA diagram. PRISMA diagram for the search strategy and selected studies. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The
PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6):e1000097.
doi:10.1371/journal.pmed1000097. For more information, visit www.prisma-statement.org
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Table 1 Characteristics of the included studies














LR 2000 0.25 BH 62.5 HSVM and TEM
2 Corbelli R (2004) [23] Switzerland Prospective Cohort 17 PCD
17 non PCD (BE,B)
All: 11.4 (1.2) CLD88sp 1.20 BH 126 TEM




NIOX Flex 0.30 BH 21.3 TEM
4 Mateos Coral D
(2011) [31]









CLD88sp 0.33 ER & TB ER: 58.5
TB: 37.1
TEM
5 Marthin JK (2011) [22]
Substudy 3
Denmark Prospective Cohort 20 PCD
97 non PCD
All: 6.9 (0.0–62.4)c NIOX Flex 0.30 BH & TB BH: 52.5
TB: 47.4
HSVM and TEM
6 Marthin JK (2011) [22]
Substudy 2




NIOX Flex 0.30 BH & TB BH: 52.5
TB: 47.4
HSVM and/or TEM
7 Leigh M (2013) [7] United States Prospective Cohort 71 PCD
84 non-PCD
PCD: 23.3(18)







ER 76.9 TEM and DNA
8 Boon M (2014) [30] Belgium Case - Control 38 PCD
188 non PCD



















0.30 BH & TB BH: 38
TB: 30
HSVM and TEM
(and culture for some)




NIOX MINO 0.30 TB 17.4 HSVM and TEM




NIOX Flex 0.28 BH 7.2 TEM
12 Moreno Caldo A
(2010) [29]








LR2000 0.25 BH 28 TEM
13 Beydon M 2015 [24] France Prospective Cohort 49 PCD
37 non-PCD
PCD: 11.4 (7,13.9)d







HSVM, TEM and/or DNA
PCD: Primary Ciliary Dyskinesia, HC: Healthy Controls, B: Bronchitis, CF: Cystic Fibrosis, BE: non CF non PCD Bronchiectasis, CSLD: Chronic Suppurative Lung Disease, HID: Humoral Immunodeficiency Disorders, TEM: Transmission
Electron Microscopy, HSVM: High Speed Video Microscopy, DNA: Genetic testing
aStudy population refers to subgroups that comparisons (sensitivity, specificity, PPV, NPV) were reported for in the original articles
















sensitivity analysis, with the exclusion of studies that
used the electrochemical devise NIOX MINO [14, 27],
the resulting estimates of overall sensitivity and overall
specificity for the non-VC maneuver do not signifi-
cantly differ from the estimates of the main analysis.
Discussion
In this meta-analysis we demonstrated that nNO meas-
urement with VC techniques has overall sensitivity of
95 % and a specificity of 94 % whereas nNO measure-
ment with the non-VC technique has comparable and
Fig. 2 Forest plots for sensitivity and specificity. Forest plot of sensitivity and specificity of nNO for detecting PCD with the 95 % CI for each population of
the included studies. a Forest plot for studies employing a VC breathing technique and b Forest plot for studies employing a non-VC breathing technique
Table 2 QUADAS-2 Quality Assessment results
Study Risk of bias Applicability concerns
Patient selection Index test Reference Standard Flow and timing Patient selection Index test Reference standard
Boon 2014 [30] L U L L L L L
Mateos Coral 2011 [31] U L L L U L L
Piacentini 2008 [25] U L L L U L L
Santamaria 2008 [28] L U L L L L L
Montela 2012 [27] U L U L L L L
Corbelli 2004 [23] L U L L L L L
Narang 2002 [26] L L L L L L L
Harris 2014 [14] L U L L L L L
Leigh 2013 [7] L L L L L L L
Marthin 2011 [22] L U L L L L L
Moreno Galdo 2010 [29] U U L L U L L
Beydon M 2015 [25] L L L U L L L
QUADAS 2 consists of four key domains covering patient selection, index test, reference standard and flow of patients through the study and timing of the index
test and reference standard (“flow and timing”). Each domain is assessed in terms of the risk of bias and the first three are also assessed in terms of concerns
regarding applicability
U: Unknown, L: Low, H: High
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very similar sensitivity (93 %) and specificity (95 %). We
applied a different approach to the one employed in a
previous report [15] and evaluated nNO diagnostic per-
formance metrics by using all the available evidence in
the literature. These summary estimates allow us to
make comparisons between the various proposed and
established diagnostic tests for PCD, which are essential
for clinical decision making. We also provide a graphical
representation of our results using the hierarchical sum-
mary receiver operating characteristic (HSROC) curve
incorporating the different cut-offs between primary
studies. The clinical utility of nNO measurement is
underlined by the high LR+ (VC: 15.8, non-VC: 18.5)
and low LR- (VC: 0.06, non-VC: 0.07), meaning that an
abnormal (low) nNO leads to a steep increase in the
post-test probability of PCD, compared to the pretest
probability, while in the case of a normal nNO measure-
ment the opposite is also true [19]. However, since the
sensitivity and specificity of the test are not 100 %, in
the presence of strong clinical suspicion for PCD [33],
even in the case of a negative nNO test, a more detailed
diagnostic work-up (HSVM, TEM, genetics) is indicated.
Current ATS/ERS recommendations for nNO include
only VC maneuvers although recent evidence [14, 30, 31],
that is supported by the results of this meta-analysis, high-
lights the discriminative ability of nNO during TB. TB is
the only method available to obtain nNO measurements
in young children (<5 years), which is particularly import-
ant as disease manifestations appear very early in life. Of
course, the validity of nNO measurements in infants
(<6 months) has been questioned, as nNO output in in-
fancy is reduced due to the partial development of parana-
sal sinuses [25] where the majority of NO is produced [11]
whereas the number of patients under 5 years which were
evaluated in these studies [14, 22, 24, 27, 30, 31] is very
small . The usefulness of nNO during TB has been dem-
onstrated in the Danish cohort of 117 consecutive refer-
rals with median age 6.9 years, where 83 % were able to
perform TB versus 50 % for BH and 31 % for ER [22].
There is evidence that patients that have earlier diagnosis
of this disease might have better clinical and functional
outcomes [34, 35] and the application of this promising
screening method in preschool children could not only lead
to diagnosis at an earlier age but could also contribute to-
wards the reduction of unnecessary cilia biopsies. Neverthe-
less, our results for the non-VC techniques should be
interpreted with caution. Their low 95 % CI limit for speci-
ficity is at 82 % which suggests that a significant number of
suspect PCD referrals is possible to give a falsely low nNO
and prompt further diagnostic testing, thus increasing costs
both to the healthcare system and the patient. Only seven
studies were eligible for inclusion in the meta-analysis of
non-VC maneuver, as opposed to 12 studies for the VC
maneuver, and the low 95 % CI limit of the former may be
due to the limited sample size. Furthermore, two of the
non-VC studies used the NIOX MINO portable device
which uses electrochemical analysis of NO as opposed to
the better validated chemiluminescence method of the
stationary devices (NIOX FLEX, Ecomedics CLD88).
Nevertheless, we performed a post hoc analysis with
the exclusion of these studies which did not influence
the diagnostic accuracy of the non-VC maneuver and
the quantitative synthesis includes data from all seven
non-VC studies.
NIOX MINO is a simpler and cheaper tool for meas-
uring nNO, and validation studies have already been
published [14, 36, 37]. However, as NIOX MINO was
designed for exhaled NO measurement in asthmatic in-
dividuals, issues relating to its accuracy [37] and repeat-
ability [14] have been reported when used for nNO
Fig. 3 VC and non-VC HSROC curves. HSROC curves for the included studies. a HSROC curve for studies employing a VC breathing technique and
b HSROC curve for studies employing a non-VC breathing technique
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measurement in subjects referred for PCD evaluation. In
addition, while the manufacturer recommends measure-
ments of nNO with BH for at least 45 s, this is usually
not possible by many patients and instead NIOX MINO
is frequently used with the alternative TB maneuver re-
gardless of patient’s age [14, 37]. These limitations ques-
tion the suitability of NIOX MINO as a stand-alone
diagnostic test and additional studies on the diagnostic
accuracy of NIOX MINO measurements during TB are
needed to confirm the validity of this method. However,
the low cost and simple use potentiate the consideration
of NIOX MINO as a promising first line screening test
in a future diagnostic algorithm for PCD.
Currently, there is no universally accepted cutoff for ab-
normally low nNO. The included studies in this meta-
analysis proposed a variety of cutoffs for nNO production
by VC (7.2–126 nl/min) and non-VC (17.4–60 nl/min)
techniques. This variability demonstrates the need for
standardization of nNO measurements and agreement on
cutoffs for the different breathing maneuvers. A recent,
large, multicenter study has proposed a cutoff equal to
77 nl/min for VC [7], whereas the meta-analysis by Collins
et al. reported that a cutoff of 75.2 nl/min would include
99.85 % of PCD patients performing VC maneuvers [15].
Regarding the non-VC maneuver however, no cutoff value
has been proposed by a large enough study, thus add-
itional studies are needed for the establishment of such
cutoffs and further standardization of the technique.
Our study has some limitations. The main limitation is
the heterogeneity and the weaknesses of the diagnostic
standard that the published studies are employing for
the definition of PCD status. As a result, the captured
spectrum of the disease might not be totally representa-
tive of the true PCD population. TEM, which is the most
commonly used test for PCD status definition in pub-
lished studies, misses approximately 30 % of patients
with PCD [38] and this should be taken into account in
the assessment of the diagnostic efficacy of nNO. How-
ever, in the sensitivity analysis, when we included the
studies that had employed more than one (in addition to
TEM) diagnostic test to establish PCD diagnosis, our re-
sults did not change substantially thus providing relative
certainty to the accuracy of nNO as a diagnostic test.
There is considerable variation between individual stud-
ies in the number of cases, total sample size and cut-off
values. However, the bivariate meta-analysis and HSROC
curve analyses take explicitly this diversity into account
and can accommodate studies with populations of differ-
ent risks and different definition thresholds. Another
issue for the synthesis of the data is that the majority of
the included studies were diagnostic case–control stud-
ies. Empirical evidence has shown that case–control
studies, as opposed to cohort studies, may overestimate
the diagnostics Odds Ratio (DOR) [39]. Nevertheless, we
think that the possibility of overestimation is limited, as
the case–control studies included here were diagnostic
studies designed to assess the test accuracy and not to
provide evidence on associations between a risk factor
and the disease [40]. Additionally, given the rarity of
PCD, it is expected that the majority of studies will have
a case–control design. Due to the same reason, both
case–control and prospective cohort studies included
relatively small numbers of subjects. However the syn-
thesis of the included studies led to the inclusion of data
for several hundreds of PCD and non-PCD subjects and
allowed the use of the appropriate statistical models and
provided the estimates we report. It should be under-
lined of course that these estimates apply provided that
the ATS/ERS guidelines are followed for the perform-
ance of the test and the obtained values are compared to
the normal values obtained from samples of healthy sub-
jects in the respective populations.
Conclusions
In summary, measurement of nNO, both with VC and
non-VC maneuvers, has high overall diagnostic accuracy
and provides a clinically significant diagnostic tool for large
uninvestigated populations of suspect cases worldwide
where access to TEM and HSVM is not easy. Furthermore,
the high overall diagnostic accuracy of nNO calls for re-
evaluation of the diagnostic accuracy of each of the avail-
able diagnostic tests for PCD (nNO, TEM and HSVM) with
the aim to develop an algorithm with the most efficacious
combination of tests to achieve PCD diagnosis.
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